Clinical trial · Interventional
Randomized Study Versus Placebo for the Prevention of Neurotoxicity Induced by Weekly PACLITAXEL
Phase II Multicentric, Randomized Study Versus Placebo for the Prevention of Neurotoxicity Induced by Weekly PACLITAXEL
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study recommends the use of OnLife dietary supplement, which will be followed by a few day before the initiation of PACLITAXEL, for the prevention of PACLITAXEL induced neuropathy. OnLife will be continued one month after stopping chemotherapy. This would limit the number of PACLITAXEL dose reductions and premature interruptions of this chemotherapy, thus potentially improving the results in terms of antitumor efficacy, while improving the quality of life of patients treated with weekly PACLITAXEL.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| OnLife® | Drug | — | UNRESOLVED |
| Placebo | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Standard chemotherapy PACLITAXEL + placebo dietary supplement
- interventionNames
- Other: Placebo
- type
- EXPERIMENTAL
- label
- OnLife®
- description
- Standard chemotherapy + OnLife® dietary supplement
- interventionNames
- Drug: OnLife®
Primary outcomes (1)
- measure
- Neuropathies will be graded by the oncologist using the NCI-CTCAE version 5.0.
- timeFrame
- At 3 months
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Months
Show eligibility criteria text
Inclusion Criteria: * Breast cancer patient with neo-adjuvant or adjuvant management, with an indication for weekly PACLITAXEL 80 mg/m² for 12 courses. * Age ≥ 18 years * Performans Status ≤ 3 according to Karnofsky and life expectancy greater than 6 months * For patients of childbearing age, effective contraception while taking Onlife®/placebo. * Patient able to swallow OnLife/placebo® tablets easily * Patient able and willing to follow all study procedures (including the completion of numerous questionnaires) in accordance with the protocol * Patient has understood, signed and dated the consent form * Patient affiliated to the social security system Exclusion Criteria: * Patient previously started on PACLITAXEL * Known allergy to any of the substances in the study product Onlife®/placebo (fish oil product) * Diabetes * Exogenous (Alcoholism) * History of peripheral neuropathy at inclusion and/or presence of sensory and/or motor disorders due to other neurological diseases * Pregnant or breastfeeding woman * Other uncontrolled progressive pathologies * Impossible or random follow-up * Persons deprived of liberty or under guardianship (including curatorship) * Inability to submit to the medical follow-up of the trial for geographical, social or psychological reasons.
References
Publications (0)
Data not yet available